Synthesis of [3H]ABT‐518, a matrix metalloproteinase inhibitor (MMPI) labeled in the phenyl rings
Authors:
- 8 January 2009
- journal article
- research article
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 52 (3) , 98-102
Abstract
A novel matrix metalloproteinase inhibitor, ABT‐518, [S‐(R*, R*)]‐N‐[1‐(2, 2‐dimethyl‐1,3‐dioxol‐4‐yl)‐2‐[[4‐[4‐(trifluoromethoxy)‐phenoxy]phenyl]sulfonyl]ethyl]‐N‐hydroxyformamide, was labeled with tritium in two phenyl rings in a seven‐step synthesis. The overall radiochemical yield of [3H]ABT‐518 in seven steps starting from 1‐(methylsulfonyl)‐4‐[4‐(trifluoromethoxy)phenoxy]benzene was 6.2% with the radiochemical purity of 99.4%. Copyright © 2009 John Wiley & Sons, Ltd.Keywords
This publication has 11 references indexed in Scilit:
- Matrix Metalloproteinase Inhibitors as Anticancer TherapeuticsCurrent Cancer Drug Targets, 2005
- The Evolution of the Matrix Metalloproteinase Inhibitor Drug Discovery Program at Abbott LaboratoriesCurrent Topics in Medicinal Chemistry, 2004
- Matrix metalloprotease inhibitors: design from structureBiochemical Society Transactions, 2004
- Synthesis of [14C]ABT‐770, matrix metalloproteinase inhibitor (MMPI), labelled in the phenoxy ringJournal of Labelled Compounds and Radiopharmaceuticals, 2003
- The Development of a Large-Scale Synthesis of Matrix Metalloproteinase Inhibitor, ABT-518Organic Process Research & Development, 2002
- 2,2,2-Trifluoroethyl Formate: A Versatile and Selective Reagent for the Formylation of Alcohols, Amines, andN-HydroxylaminesOrganic Letters, 2001
- Phenoxyphenyl SulfoneN-Formylhydroxylamines (Retrohydroxamates) as Potent, Selective, Orally Bioavailable Matrix Metalloproteinase InhibitorsJournal of Medicinal Chemistry, 2001
- Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes11Abbreviations: MMP, matrix metalloproteinase; MMPI, matrix metalloproteinase inhibitor; DMEM, Dulbecco’s modified Eagle’s medium; FBS, fetal bovine serum; NBD-PE, N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine; and MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; DMSO, dimethylsulfoxide; HPLC, high performance liquid chromatography.Biochemical Pharmacology, 2001
- Emerging Therapeutic Advances for the Development of Second Generation Matrix Metalloproteinase InhibitorsCurrent Pharmaceutical Design, 1997
- Synthesis of (.+-.)-Combretastatin D-1 and Combretastatin D-2The Journal of Organic Chemistry, 1994